Compare Merck & Co., Inc. (MRK) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Snowflake Inc — how do they compare? Merck & Co., Inc. trades at $145.85 (market cap $351.28B), while Snowflake Inc trades at $362.15 (market cap $121.15B). The key difference: Merck & Co., Inc. is far larger — about 2.9× Snowflake Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Snowflake Inc for 54 Days on average.
| MRK | SNOW | |
|---|---|---|
Market Cap | $351.28B | $121.15B |
Volume | 7,969,665 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $156.43 | $356.47 |
52-Week Low | $82.49 | $121.11 |
Typical Hold Time | 98 Days | 54 Days |
Enterprise Value | $398.04B | $121.57B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Snowflake (SNOW) trades at $360.12, up 8.19% in the past 24 hours, with strong technical momentum and bullish moving average signals. The company continues to show impressive revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a net loss of $1.29 billion. Recent developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath, while analysts maintain strong buy sentiment with an $418.03 consensus price target.
Snowflake presents a growth investment opportunity with accelerating revenue expansion and positive earnings beats, but faces significant execution risk due to persistent losses and high valuation multiples. The stock's 81% analyst buy rating reflects confidence in the company's AI data cloud positioning, though investors must weigh the premium valuation against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
